Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer’s and other neurodegenerative diseases
| Autor: | Steffen, Halbgebauer, Petra, Steinacker, Daniel, Riedel, Patrick, Oeckl, Sarah, Anderl-Straub, Jolina, Lombardi, Christine A F, von Arnim, Magdalena, Nagl, Armin, Giese, Albert C, Ludolph, Markus, Otto |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Amyloid beta-Peptides
cerebrospinal fluid [Neurocalcin] Cognitive Neuroscience diagnosis [Alzheimer Disease] Neurodegenerative Diseases CSF cerebrospinal fluid [Amyloid beta-Peptides] Biomarker Prognosis cerebrospinal fluid [Alzheimer Disease] Blood cerebrospinal fluid [Biomarkers] Neurology Alzheimer Disease Neurocalcin Diagnosis VILIP-1 Humans ddc:610 Neurology (clinical) Neurodegeneration Alzheimer’s disease Biomarkers |
| Zdroj: | Alzheimer's research & therapy 14(1), 175 (2022). doi:10.1186/s13195-022-01122-4 |
| ISSN: | 1758-9193 |
| DOI: | 10.1186/s13195-022-01122-4 |
| Popis: | Background Visinin-like protein 1 (VILIP-1) belongs to the group of emerging biomarkers with the potential to support the early diagnosis of Alzheimer’s disease (AD). However, studies investigating the differential diagnostic potential in cerebrospinal fluid (CSF) are rare and are not available for blood. Methods We set up a novel, sensitive single molecule array (Simoa) assay for the detection of VILIP-1 in CSF and serum. In total, paired CSF and serum samples from 234 patients were investigated: 73 AD, 18 behavioral variant frontotemporal dementia (bvFTD), 26 parkinsonian syndromes, 20 amyotrophic lateral sclerosis (ALS), 22 Creutzfeldt-Jakob disease (CJD), and 75 non-neurodegenerative control (Con) patients. The differential diagnostic potential of CSF and serum VILIP-1 was assessed using the receiver operating characteristic curve analysis and findings were compared to core AD biomarkers. Results CSF and serum VILIP-1 levels correlated weakly (r=0.32 (CI: 0.20–0.43), ppppp Conclusions We here report on the successful establishment of a novel Simoa assay for VILIP-1 and illustrate the potential of CSF and serum VILIP-1 in the differential diagnosis of AD with highest levels in CJD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink